Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Using complement inhibition to reduce inflammation after subarachnoid hemorrhage

Official title: A Phase II Trial on the Safety and Efficacy of C1 Inhibitor for the Acute Management of Subarachnoid Hemorrhage

Run by Haaglanden Medical Centre · NCT06359782 · Data updated 2026-11-12

This study is testing if a new treatment can help reduce inflammation and improve recovery in patients with bleeding in the brain caused by an aneurysm.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment128 (estimated)
SponsorHaaglanden Medical Centre
Academic / other
Locations1 site (The Hague, South Holland)
StatusRecruiting
StartedNovember 4, 2024
Main results expectedMarch 2027
Study endsMarch 2027
Registry record updatedDecember 27, 2024
Trial IDNCT06359782 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with a confirmed diagnosis of aneurysmal subarachnoid hemorrhage.

Probably not a fit

Patients with subarachnoid hemorrhage of non-aneurysmal origin or those with a very poor prognosis are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of C1-inhibitor Cinryze in patients diagnosed with aneurysmal subarachnoid hemorrhage (SAH). The study aims to determine if inhibiting the complement system can limit delayed cerebral ischemia and improve clinical outcomes by reducing neuroinflammation. Participants will receive either the C1-inhibitor or a placebo, and their progress will be monitored to assess the treatment's effectiveness. The trial focuses on patients with varying degrees of SAH severity as classified by the WFNS grading system.

Why it matters

Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients suffering from aneurysmal subarachnoid hemorrhage.

How similar studies have gone: While the approach of complement inhibition is being explored, this specific application in SAH is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Confirmed diagnosis of aneurysmal subarachnoid hemorrhage on CT-scan;
* Age ≥ 18 years on admission;
* WFNS grade 1-5.

Exclusion Criteria:

* Subarachnoid hemorrhage deemed most likely of 'peri mesencephalic' origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (not originated from an aneurysm and patients have by definition a favourable clinical outcome)
* Subarachnoid hemorrhage deemed most likely of post-traumatic origin after consideration of history, clinical examination and radiological findings (including angiographic imaging); (does not occur spontaneous)
* Participation in another clinical therapeutic study;
* Patients with definite infaust prognosis on arrival and/or expected death within 24 hours of admission
* Patients with a known hereditary complement deficiency (including hereditary angioedema);
* Patients with a history of sensibility to blood products or C1-inhibitor;
* Patients with a history of thrombosis (when known at time of inclusion);
* Pregnant woman

Where it's running

  • Haaglanden Medical Centre
    The Hague, South Holland, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.